18F-FDG PET/CT for Oncological Patients: Procedural Guideline by the Korean Society of Nuclear Medicine Version 2.0
Authors:
Open Access
- 17 July 2025
- journal article
- research article
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 59 (6) , 377-388
Abstract
The Korean Society of Nuclear Medicine (KSNM) was founded in 1961 to promote the clinical and technical advancement of nuclear medicine in Republic of Korea. It comprises approximately 600 members, mainly nuclear medicine physicians and related scientists. The KSNM periodically updates guidelines to advance nuclear medicine and help medical professionals provide better patient care. These guidelines are flexible and not obligatory. The KSNM states that these guidelines should not be used in legal actions challenging the medical decisions of healthcare professionals. Final medical decisions should be made by nuclear medicine physicians based on individual patient conditions, available resources, the latest medical knowledge, and technological advances. Deviations from these guidelines does not necessarily indicate substandard care, but rather reflects the application of reasonable clinical judgment. Detailed quality control is to follow the KSNM’s quality control guidelines. Due to the diversity of patients and complexity of medical cases, adherence to guidelines does not always guarantee accurate diagnoses or successful outcomes. This guideline aims to revise the 2013 ‘ 18 F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Oncological Patients: Procedural Guideline by the KSNM’, ensuring medical professionals take appropriate actions based on current medical knowledge, available resources, and patient needs, ultimately achieving effective and safe imaging. Clinical Trial Number : Not applicable.Keywords
This publication has 79 references indexed in Scilit:
- Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [18F]FDG‐PET imaging. Is it of value in asymptomatic patients?Pediatric Blood & Cancer, 2017
- The clinical impact of 18F–FDG PET/CT in extracranial pediatric germ cell tumorsPediatric Radiology, 2017
- Staging Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAYAHL): Methodology statementPediatric Blood & Cancer, 2017
- Comparison of18F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent OsteosarcomaPediatric Blood & Cancer, 2016
- Time-dependent changes in 18F-FDG activity in the thymus and bone marrow following combination chemotherapy in paediatric patients with lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Exploratory evaluation of two-dimensional and three-dimensional methods of FDG PET quantification in pediatric anaplastic astrocytoma: a report from the Pediatric Brain Tumor Consortium (PBTC)European Journal of Nuclear Medicine and Molecular Imaging, 2008
- PET-CT in pediatric Langerhans cell histiocytosisPediatric Radiology, 2007
- A gradient-based method for segmenting FDG-PET images: methodology and validationEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trialEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- FDG PET imaging for grading and prediction of outcome in chondrosarcoma patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004